Improving the Continuum of Care in Alcohol Dependence: Latest Evidence for Counselors and Clinicians
neuroscienceCME Webcast
Premiere Date: Friday, January 18, 2008This activity offers CE credit for:
- Physicians (ACCME/AMA PRA Category 1)
- Nurses (CNE)
- Pharmacists (ACPE)
- Psychologists (APA)
- Social Workers (NASW)
- Addiction Professionals (NAADAC)
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Sunday, January 18, 2009
Note: Credit Is No Longer Available
 | Kyle M. Kampman, MD Associate Professor, Department of Psychiatry University of Pennsylvania School of Medicine Medical Director, University of Pennsylvania Treatment Research Center Medical Director, Charles O'Brien Center for the Treatment of Addictions Philadelphia, PA |
 | Gail Kaempf, MSN, CRNP Nursing Services Manager University of Pennsylvania Treatment Research Center Philadelphia, PA |
According to a survey by the National Epidemiologic Survey on Alcohol and Related Conditions, approximately 8 million
individuals in the United States are alcohol dependent. It is estimated that only 2.4 million individuals received treatment in 2004
for alcohol dependence, and of those in treatment, less than 20% received a medication to assist their quit attempt.(1) Clinicians
and counselors continue to struggle with the need to close the gap between the number of people who are alcohol dependent
and those who actually receive treatment.(2)
In a study by Anton and colleagues, it was demonstrated that patients who were given a combination of pharmacotherapy and
psychosocial treatment were less likely to relapse. Those who did relapse experienced a longer time between relapses.(3) This
study demonstrates the underlying impact that neurobiology can have on recovery. Overall, psychosocial interventions target
the cortex, the center for decision-making; whereas, pharmacotherapy targets the limbic region, associated with brain reward
pathways.
In this evidence-based, interactive format, faculty will explore the integration of pharmacotherapy into current treatment models
to optimize patient outcomes. Faculty will also utilize patient case studies as examples to guide counselors and clinicians in the
development of individualized treatment strategies.
- Williams SH. Medications for treating alcohol dependence. Am Fam Physician 2005;72:1775-1780.
- Substance Abuse and Mental Health Services Administration, Office of Applied Studies, Substance Dependence, Abuse and Treatment Tables; 2004. Available at: http://oas.samhsa.gov/nsduh/2k4tabs/Sect5peTabs1to99.htm#tab5.49a. Accessed August 28, 2007.
- Anton RF, et al. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol 2005;25:349-357.
To examine the importance of neurobiology in addiction and to identify evidence-based psychosocial intervention and pharmacotherapy management strategies to improve outcomes for patients with alcohol dependence.
At the end of this CE activity, participants should be able to:
- Recognize the importance of neurobiology in addiction.
- Review the evidence for various psychosocial interventions in patients with alcohol dependence.
- Discuss the FDA-approved pharmacotherapies for patients with alcohol dependence.
- Evaluate the evidence for the efficacy of combination pharmacotherapy and psychosocial interventions in patients with alcohol dependence.
Physicians, physician assistants, nurse practitioners, nurses, psychologists, social workers, certified case managers, pharmacists, addiction professionals, and other healthcare professionals with an interest in managing alcohol dependence.
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education to provide
continuing medical education for physicians.
CME Outfitters, LLC, designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should
only claim credit commensurate with the extent of their participation in the activity.
CNE Credit (Nurses):
CME Outfitters, LLC, is an approved provider of continuing nursing education by the New York State Nurses Association, an
accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
It has been assigned code 6WASUP-PRV-0617. 1.0 contact hours will be awarded upon successful completion.
Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.
CEP Credit (Psychologists):
CME Outfitters is approved by the American Psychological Association to sponsor continuing education for psychologists.
CME Outfitters maintains responsibility for this program and its content. (1.0 CE credits)
NASW Credit (Social Workers):
This program was approved by the National Association of Social Workers (provider #886407722) for 1 continuing education
contact hour.
NAADAC Credit (Addiction Professionals):
CME Outfitters, LLC, is an approved education provider by NAADAC, the Association for Addiction Professionals. Provider Number 636. This activity is designated for 1.0 contact hour.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.0 contact hours (0.1 CEUs)
Universal Program Number: 376-000-07-019-H01-P
Post-tests, credit request forms, and activity evaluations can be completed online at www.neuroscienceCME.com (click on the Testing/Certification link under the Activities tab - requires free account activation), and participants can print their certificate or statement of credit immediately (70% pass rate required).
Kyle M. Kampman, MD
A board-certified psychiatrist specializing in addiction psychiatry, Dr. Kampman received his medical degree from Tulane
University School of Medicine. He interned at the National Naval Medical Center in Bethesda, Maryland, and served as a general
medical officer in the Navy until 1990. He completed his residency in psychiatry and fellowship in addiction psychiatry at the
University of Pennsylvania.
Currently, Dr. Kampman is Medical Director of the Charles O’Brien Center for the Treatment of Addictions, Associate Professor of
Psychiatry, and Medical Director of the Treatment Research Center at the University of Pennsylvania in Philadelphia. His research
interests include pharmacotherapy for cocaine dependence and cocaine withdrawal syndrome.
Dr. Kampman and his colleagues at the Treatment Research Center developed a scale that measures cocaine withdrawal
symptom severity, the Cocaine Selective Severity Assessment (CSSA). He has written several papers showing that cocaine
withdrawal symptom severity, measured by this scale, can predict outcome in cocaine dependence treatment. He has also used
this scale to identify a subgroup of cocaine-dependent patients who appear to respond well to medications aimed at reducing
cocaine withdrawal symptoms such as amantadine and propranolol.
Dr. Kampman recently completed a successful pilot trial of topiramate for relapse prevention in the treatment of cocaine
dependence. Based on the positive results of the pilot study and results from the University of Texas showing topiramate’s
efficacy for the treatment alcohol dependence, Dr. Kampman received a grant from NIAAA funding a study of topiramate for
alcoholism and comorbid cocaine dependence.
Dr. Kampman currently serves on the editorial board of the Journal of Addiction Medicine and is an active member of the
American Society of Addiction Medicine, College on Problems of Drug Dependence, and the Pennsylvania Society of Addiction
Medicine. His contributions to the field have been acknowledged by the Scott Mackler Award for Excellence in Substance Abuse
Teaching presented by the University of Pennsylvania School of Medicine and the Caron Foundation’s Medical Professional-
Physician Award.
Gail Kaempf, MSN, CRNP
Ms. Kaempf is currently the nursing services manager at the University of Pennsylvania Treatment Research Center (TRC). In
addition to her management role, she provides direct care for study subjects in addiction clinical studies. Ms. Kaempf has also
been a speaker for NAADAC, presenting on pharmacotherapy for alcohol disorders. Prior to her role as a family nurse practitioner,
Ms. Kaempf was the perioperative clinical nurse specialist at an urban hospital. She has done extensive lecturing in the field of
perioperative nursing and has co-authored several articles.
Christopher W. Shea, MA, CRAT, CAC-AD
Mr. Shea is currently the Clinical Director of Fr. Martin’s Ashley. In this capacity, he oversees all aspects of the treatment program
for Ashley, one of the premier residential alcohol and drug rehabilitation facilities in the world. He has been a member of the
counseling staff since 2001. Mr. Shea brings 14 years of experience, working in Baltimore City and Baltimore County as a chemical
dependency counselor and administrator prior to coming to Ashley. Mr. Shea received his BA in Philosophy (with a concentration
in Clinical Psychology) from St. Hyacinth College in MA, and his Masters in Pastoral Studies from the Washington Theological
Union in Washington, D.C. In addition, he is State certified as a Chemical Dependency Counselor, Board approved as a Chemical
Dependency Supervisor, and Nationally certified as a Rational Addictions Therapists. He also serves as an Adjunct Professor of
Chemical Dependence at Baltimore City Community College; sits on various Boards, and is published in the field of Chemical
Dependency.
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all its CE
activities. Faculty must disclose to the participants any significant relationships with commercial companies whose products or
devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has
evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure,
use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant
information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Kampman has disclosed that he receives grants from Alkermes, Inc. He is also on the speakers bureaus of Cephalon, Inc., Forest
Pharmaceuticals, Inc., and Reckitt Benckiser PLC.
Ms. Kaempf has no financial relationships to disclose in regard to the products and/or services discussed in this activity.
Mr. Shea has no financial relationships to disclose in regard to the products and/or services discussed in this activity.
Unlabeled Use Disclosure
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The
faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational
uses (any uses not approved by the FDA) of products or devices.
CME Outfitters, LLC, the faculty, Cephalon, Inc., and Alkermes, Inc., do not endorse the use of any product outside of the FDA
labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during
this activity without evaluation of their patient for contraindications or dangers of use.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
GRV-001-011808-15
